Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498289 | 1.00 | NTRK1 (0.47) | NTRK1KCNH2HRH3BACE1IGF1R | |
| SCHEMBL9937979 | 0.96 | NTRK1 (0.42) | NTRK1BACE1SMN1; SMN2KDM4EMAP3K12 | |
| SCHEMBL9943575 | 0.87 | MAPK14 (0.44) | NTRK1KCNH2ALDH1A1KDM4EMAP3K12 | |
| SCHEMBL19130834 | 0.86 | HRH3 (0.50) | HRH3 | |
| SCHEMBL17453658 | 0.85 | KDM4E (0.45) | BACE1ALDH1A1SMN1; SMN2KDM4ERECQL | |
| SCHEMBL29498278 | 0.83 | BACE1 (0.42) | KCNH2HRH3BACE1IGF1RALDH1A1 | |
| SCHEMBL17434771 | 0.83 | BACE1 (0.42) | KCNH2HRH3BACE1IGF1RALDH1A1 | |
| SCHEMBL22137743 | 0.82 | NTRK1 (0.51) | NTRK1HRH3ALDH1A1KDM4E | |
| SCHEMBL9943213 | 0.82 | KDM4E (0.42) | NTRK1KCNH2BACE1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22137746 | 0.80 | MAP3K12 (0.43) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117205212-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-12 | — | — | CN | claimed |
| CN-107207463-B | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-10-24 | — | — | CN | claimed |
| EP-3169328-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2022-03-09 | — | — | EP | claimed |
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2019-10-08 | — | — | US | claimed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | claimed |
| EP-3169328-A2 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-05-24 | — | — | EP | claimed |
| WO-2016009065-A2 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2016-01-21 | — | — | WO | claimed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | claimed |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | ABIVAX (FR) | 2025-03-27 | — | — | US | disclosed |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | ABIVAX (FR) | 2025-01-21 | — | — | US | disclosed |
| EP-3998070-B1 | MIR-124 AS A BIOMARKER FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2024-12-18 | — | — | EP | disclosed |
| CN-117568459-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| EP-3169328-A2 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016009065-A2 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2016-01-21 | — | — | WO | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | NR1I3, NR3C2, NR1I2 | NTRK1 4147/4885KCNH2 853/4885HRH3 158/4885 |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | CD14, MYADM, SYNCRIP | NTRK1 3654/4885KCNH2 2236/4885HRH3 993/4885 |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | SSB, SYVN1, TLR7 | NTRK1 3956/4885KCNH2 2385/4885HRH3 500/4885 |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | NR1I2, NR3C2, NR1I3 | NTRK1 4110/4885KCNH2 865/4885HRH3 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.